| First Author | Saito M | Year | 2014 |
| Journal | Carcinogenesis | Volume | 35 |
| Issue | 11 | Pages | 2452-6 |
| PubMed ID | 25064355 | Mgi Jnum | J:215989 |
| Mgi Id | MGI:5607463 | Doi | 10.1093/carcin/bgu158 |
| Citation | Saito M, et al. (2014) A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis 35(11):2452-6 |
| abstractText | Oncogenic fusion of the RET (rearranged during transfection) gene was recently identified as a novel driver gene aberration not only for the development of thyroid carcinoma but also of lung adenocarcinoma, the most frequent histological type of lung cancer. This study constructed and analyzed transgenic mice expressing KIF5B-RET, the predominant form of RET fusion gene specific for lung adenocarcinoma, under the control of the SPC (surfactant protein C) gene promoter. The mice expressed the KIF5B-RET fusion gene specifically in lung alveolar epithelial cells, and developed multiple tumors in the lungs. Treatment of the transgenic mice with vandetanib, which is a RET tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of thyroid carcinoma, for 8 or 20 weeks led to a marked reduction in the number of lung tumors (3.3 versus 0 and 6.5 versus 0.2 per tissue section, respectively; P < 0.01, t-test). The results suggest that the RET fusion functions as a driver for the development of lung tumors, whose growth is inhibited by RET tyrosine kinase inhibitors. |
